Sripad Ram | Digital pathology and image analysis group lead
Pfizer

Sripad Ram, Digital pathology and image analysis group lead, Pfizer

Sripad Ram heads the digital pathology and image analysis group in Drug Safety R&D at Pfizer. His research interests include digital scoring of IHC biomarkers, AI/ML algorithm development for whole-slide image analysis, and the development of 3D imaging and image-analysis tools for histopathology specimens. He received his PhD in Bioengineering from UT Southwestern Medical Center and continued his postdoctoral research at the same institution as a National Multiple Sclerosis Society Postdoctoral Fellow. Prior to joining Pfizer, he worked at Carl Zeiss Inc as a microscopy systems specialist.

Appearances:



Festival of Biologics Day 2 @ 16:30

PD-L1 glycosylation and IHC detection: is the absence of evidence the evidence of absence?

    PD-L1 CDx assays are critical for patient selection for anti PD1/PD-L1 checkpoint inhibitor treatment. Recently, it was reported that post translational modifications on PD-L1 can affect antibody detection thereby resulting in false negative diagnosis in a PD-L1 CDx  assay. Using whole slide digital image analysis, quantitative mass spectroscopy and immunohistochemistry, we have developed and validated a multimodality workflow to quantitatively characterize total and glycosylated PD-L1 levels in FFPE tumor resections. We have investigated the impact of PD-L1 glycosylation on the detection sensitivity for two different PD-L1 antibody clones (73-10 and SP263) that are used in CDx assays and demonstrate that these clones are not affected by this post-translational modification. 
last published: 27/Mar/24 15:25 GMT

back to speakers